Literature DB >> 15341972

Targeting the IGF-1 receptor: from rags to riches.

Renato Baserga.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15341972     DOI： 10.1016/j.ejca.2004.06.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  8 in total

1.  Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.

Authors:  Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S Dimitrov; Seiichi Saito; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

2.  Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma.

Authors:  Shucheng Yin; Ada Girnita; Thomas Strömberg; Zahidul Khan; Sandra Andersson; Huiyuan Zheng; Christer Ericsson; Magnus Axelson; Monica Nistér; Olle Larsson; Tomas J Ekström; Leonard Girnita
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

3.  Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours.

Authors:  P Kornprat; P Rehak; J Rüschoff; C Langner
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

Review 4.  Regulation of breast cancer metastasis by IGF signaling.

Authors:  Deepali Sachdev
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

Review 5.  Novel targets with potential therapeutic applications in osteosarcoma.

Authors:  Chand Khanna
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

6.  Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications.

Authors:  Xiaoying Feng; Eiman Aleem; Yingbo Lin; Magnus Axelson; Olle Larsson; Thomas Strömberg
Journal:  Int J Oncol       Date:  2011-12-06       Impact factor: 5.650

7.  Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.

Authors:  Nikolaos Ioannou; Alan M Seddon; Angus Dalgleish; David Mackintosh; Helmout Modjtahedi
Journal:  BMC Cancer       Date:  2013-01-31       Impact factor: 4.430

8.  Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

Authors:  Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin
Journal:  Cancers (Basel)       Date:  2011-07-26       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.